Alpha 2 delta (α<sub>2</sub>δ) ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome

Jeremy D. Gale<sup>1</sup> and Lesley A. Houghton<sup>2,3</sup>*

<sup>1</sup>Clinical Research, Pfizer Global Research and Development, Sandwich, UK
<sup>2</sup>Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Jacksonville, FL, USA
<sup>3</sup>Translational Medicine, University of Manchester, Manchester, UK

Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain and altered bowel habit, and often associates with other gastrointestinal symptoms such as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also frequently coexists with conditions that may also involve central sensitization processes, such as fibromyalgia, irritable bladder disorder, and chronic cough. This review examines the evidence to date on gabapentin and pregabalin which may support further and continued research and development of the α<sub>2</sub>δ ligands in disorders characterized by visceral hypersensitivity, such as IBS. The distribution of the α<sub>2</sub>δ subunit of the voltage-gated calcium channel, possible mechanisms of action, pre-clinical data which supports an effect on motor–sensory mechanisms and clinical evidence that points to potential benefits in patients with IBS will be discussed.

Keywords: α<sub>2</sub>δ ligands, gabapentin, pregabalin, irritable bowel syndrome, visceral sensitivity, central sensitization, peripheral sensitization, motility

INTRODUCTION
ABDOMINAL PAIN AND VISCERAL HYPERSENSITIVITY
Abdominal pain and discomfort along with altered bowel habit are integral to the diagnosis of irritable bowel syndrome (IBS). Although disordered bowel habit can often be improved in these patients, efficacious treatment of pain, abdominal discomfort, and associated symptoms, such as bloating, remains challenging. The identification and development of new drugs to treat these symptoms has been largely unsuccessful and remains problematic, probably linked to the complexity of the functional gastrointestinal disorders (FGIDs) in which multiple factors appear to contribute to their equally multifarious pathophysiology. For example, genetic predisposition, infection, and traumatic events in early life may all predispose individuals to developing IBS, whilst chronic stress, psychological symptoms, and maladaptive coping mechanisms can increase the frequency and severity of symptoms (Ley et al., 2006; Chitkara et al., 2008; Saito and Talley, 2008; Spiller and Garsed, 2009). Pathophysiology identified to date include gastrointestinal dysmotility, abnormalities in the inflammatory/immune system, increased intestinal permeability, unstable or altered enteric flora, psychopathology, visceral and somatic hypersensitivity, and abnormal CNS processing (Longstreth et al., 2006; Spiller et al., 2007). Although not all abnormalities are present in all patients, visceral hypersensitivity which often associates with the symptoms of pain (Posserud et al., 2007) and bloating (Posserud et al., 2007; Agrawal et al., 2008) and which is often exacerbated by stress, is thought by many to be a determinant or biological measure of IBS (Mertz et al., 1995; Bouin et al., 2002). For example, Mertz et al. (1995) showed altered rectal perception in almost all IBS patients in the form of either lowered sensory thresholds, increased sensation intensity or altered viscerosomatic referral, whilst Bouin et al. (2002) suggested that a pain threshold of less than 40 mmHg in the rectum correctly identified IBS from non-IBS subjects. In addition, whilst only approximately half of IBS patients appear to exhibit lowered rectal sensory thresholds to balloon distension (Whitehead and Palsson, 1998; Posserud et al., 2007), almost all patients (70%) show hypersensitivity elsewhere in the gastrointestinal tract, especially in the jejunum (Francis et al., 1995; Hammonds et al., 1998). Moreover, in the latter studies (Francis et al., 1995; Hammonds et al., 1998) within the group as a whole, and especially in those subjects with diarrhea, lower pain thresholds were observed throughout the entire GI tract compared with healthy controls.

CENTRAL SENSITIZATION
These observations of pan-gastrointestinal visceral hypersensitivity and increased viscerosomatic referral, along with reported increases in expression of extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain and back pain (Whorwell et al., 1986; Mayer and Gebhart, 1994), and presence of fibromyalgia in some patients (Whitehead et al., 2002; Almansa et al., 2009) are consistent with a widespread aberrant central processing of pain (central sensitization) in these patients. Further support is provided by the observations that whilst healthy volunteers exhibit an inhibition of the somatic nociceptor flexion reflex (R-III) to slow ramp distension of the rectum, IBS
patients exhibit a facilitation of this reflex, suggesting enhanced spinal processing in IBS (Coffin et al., 2004). In addition, there are an increasing number of studies suggesting that IBS patients may also be hypersensitive to somatic stimuli. One such study, showed hypersensitivity to rectal balloon distension and cutaneous thermal stimulation of the hand and foot in IBS compared with control subjects (Verne et al., 2001). Interestingly foot hypersensitivity was greater than hand hypersensitivity, suggesting greater convergence and overlap of rectal and foot afferents at common lumbosacral levels (greater central hyperalgesia) than rectal and hand afferents at the levels of the cervical spinal (Verne et al., 2001).

POSSIBLE SYNERGISTIC MECHANISMS
Along with the spinal (central) sensitization, other possible synergistic mechanisms of visceral hypersensitivity include disturbances in the cognitive and emotional aspects of pain (e.g., hypervigilance, somatization, catastrophizing, depression), alterations in descending excitatory and inhibitory pathways (e.g., diffuse noxious inhibitory control, DNIC), and sensitization of afferent nerves (e.g., peripheral sensitization due to for example mucosal insult). A quantitative meta-analysis of functional neuroimaging studies in IBS patients during rectal distension showed greater recruitment of attentional (lateral prefrontal cortex), affective (ventral anterior cingulated cortex [ACC], amygdala, dorsal pons), and homeostatic afferent circuits (insula, dorsal ACC, thalamus) compared with controls, with increased regional activity in the insula (INS) and anterior midcingulate cortex (aMCC) being most commonly reported (Labus et al., 2009). More recent studies investigating anatomical differences in the brain between IBS and control subjects have shown morphometric changes in gray matter density predominantly in areas involved in cognition and evaluation, with changes in other areas of the brain being generally explained by anxiety and depression levels in the IBS patients (Seminowicz et al., 2010). In another study by Heymen et al. (2010), in which DNIC was assessed in IBS compared with healthy subjects by measuring the reduction in left hand thermal pain intensity during counter irritation by submersion of the right hand in 12°C water (conditioning stimulus, CS), and controlling for the non-specific effects on pain perception, such as distraction from the CS, psychological symptoms, and cardiovascular reactivity, it was shown that IBS patients demonstrate deficient DNIC probably attributed to disordered central analgesic mechanisms. This deficit has subsequently been shown to directly correlate with visceral hypersensitivity (Piche et al., 2010). Indeed in the morphological study described above significant reductions in gray matter density were observed in the periaqueductal gray, an area known to play a major role in descending pain modulation, which was independent of anxiety and depression (Seminowicz et al., 2010). Other studies have shown that peripheral mucosal insults, such as the presence of inflammation, injury or excess acid do not only increase pain sensitivity at the site of injury (primary hyperalgesia/peripheral sensitization) but also at more remote sites in the gastrointestinal tract (secondary hyperalgesia), via the process of central sensitization (Anand et al., 2007; Knowles and Aziz, 2009). One example in FGIDs, is the observation that pain thresholds to electrical stimulation were not just reduced at the distal end of the esophagus where acid was infused but also in the unexposed proximal esophagus of patients with non-cardiac chest pain, with this sensitization process being significantly magnified and prolonged compared with healthy volunteers (Sarkar et al., 2000). Another possible example is the onset of IBS following GI infection (post-infectious IBS) where persistent sensitization of the primary afferents due to for example increased mast cells numbers, T lymphocytes, and expression interleukin (IL)-1β (peripheral sensitization), especially in the presence of risk factors such as depression, hypochondriasis, and adverse life events (Spiller and Garsed, 2009), could lead to central sensitization and the persistence of symptoms, allosynia (pain to a stimulus that does not normally provoke pain), hyperalgesia (increase in intensity of pain to a stimulus that normally provokes pain), and dysmotility long after the resolution of illness.

Thus there appears to be a dyssynergy between the interaction of peripheral and central pain mechanisms, along with influences from cognitive and emotional factors, and abnormalities in descending inhibitory pathways that may all lead to the sensation of abdominal pain and hypersensitivity in IBS. Central mechanisms perhaps play a pivotal role integrating between these processes and thus may represent a promising target for the development of drugs for the treatment of IBS. For a more detailed discussion of central, peripheral, and psychological processes in IBS see the reviews Van Oudenhoew and Aziz (2009), Knowles and Aziz (2009), and Anand et al. (2007).

α2δ BINDING SITES
Gabapentin (Neurontin) was first introduced as an antiepileptic drug but has more recently been used in the treatment of postherpetic neuralgia, diabetic neuropathy, migraine prophylaxis, and chronic pain conditions (Taylor, 2009; Tzellos et al., 2010). Pregabalin (Lyrica) is a second-generation compound structurally related to gabapentin and approved in the US for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for adults with partial onset seizures and for generalized anxiety disorder (GAD). In Europe pregabalin is approved for the treatment of neuropathic pain, epilepsy, and generalized anxiety disorder (Taylor, 2009; Tzellos et al., 2010). It has been, or is being, assessed in many clinical trials for disorders such as IBS and neuropathic pain in acute spinal cord injury (see US National Institute of Health, www.ClinicalTrials.gov). Pregabalin has been shown to be 2–10 times more potent than gabapentin and to possess more linear pharmacokinetics (Ben-Menachem, 2004; Huckle, 2004; Taylor, 2009; Tzellos et al., 2010).

Although structurally related to y-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the CNS, gabapentin, and pregabalin are functionally inactive at GABAα, GABAβ, or benzodiazepine receptors, and are not converted metabolically into GABA or a GABA receptor agonist (Ben-Menachem, 2004; Huckle, 2004; Taylor, 2009; Tzellos et al., 2010). In addition, clinically effective concentrations of gabapentin and pregabalin have been shown to have no effect on GABA synthesis, uptake or degradation (Ben-Menachem, 2004; Huckle, 2004; Field et al., 2006; Taylor, 2009; Tzellos et al., 2010).

Both gabapentin and pregabalin bind with high affinity to α2δ subunits of voltage-gated calcium channels and this has been
proposed as a likely site of their action. Further, in mice with mutations of the α2δ subunits that prevent drug binding, pregabalin and gabapentin are devoid of analgesic and anticonvulsant activity (Field et al., 2006). Voltage-gated calcium channels are ubiquitous in the body and are made up of an α1 subunit, which makes up the ion-conducting pore, coupled together with other subunits including β, γ, and α2δ. There is great heterogeneity within the family of α1 subunits, of which 10 members have been described in mammals (for review; Catterall et al., 2005). The α2δ subunit appears to play a role not only in the operational characteristics of individual channels, but also to enhance trafficking of the α1 subunits to the cell membrane, so influencing the number of functional calcium channels (Hendrich et al., 2008; Mich and Horne, 2008). The α2δ subunit exists as four distinct subtypes and these are encoded by four distinct genes (Klugbauer et al., 1999; Qin et al., 2002). Only subtypes 1 and 2 have been shown to exhibit binding for gabapentin and pregabalin and therefore might be expected to underwrite the analgesic, anticonvulsant, and anxiolytic activity of these drugs (Gong et al., 2001; Qin et al., 2002).

Despite the widespread localization of voltage-gated calcium channels, the focus of studies to map the distribution of the α2δ subunit has largely been restricted to tissues of the central nervous system. This distribution has been confirmed at the protein level using immunostaining with an antibody specific for gabapentin and pregabalin. In cell or neuronal cultures and in untreated animals (Fehrenbacher et al., 2003). If confirmed in additional studies, these observations might help explain the increased efficacy of gabapentin and pregabalin in humans (Gong et al., 2001). The absence of α2δ-subtype 2 in human jejunum was also confirmed at the protein level.

The functional consequences of the binding of gabapentin/ pregabalin with the α2δ protein remain controversial. Data from recombinant systems suggests that the function of the α2δ subunit is heavily dependent on the subtype of α1 protein with which the α2δ subunit is co-expressed and the cell system into which the proteins are engineered. However, it is widely accepted that the mechanism of action of these agents involves a modulation of calcium conductance, but the precise mechanism for this remains to be elucidated. The modulation of calcium currents by gabapentin has been demonstrated in several studies of isolated neurones (Stefani et al., 1998; Sutton et al., 2002; van Hooft et al., 2002), although other studies have struggled to demonstrate such an effect (Schlicker et al., 1985). More recently, it has been proposed that gabapentin may exert an action through binding to the α2δ subunit within the cytosol, rather than at the cell surface, and that this interaction can over time reduce the trafficking of α1/α2δ complexes to functional sites within the cell membrane (Hendrich et al., 2008; Mich and Horne, 2008). Thus gabapentin and pregabalin may exert a range of effects, either acute or chronic, mediated through diverse mechanisms, to modulate calcium flux in nerve terminals. The consequences of this disruption of calcium-mediated membrane depolarization have been investigated extensively. Both gabapentin and pregabalin have been shown to inhibit the release of a wide range of neurotransmitters including noradrenaline, dopamine, 5-HT, acetylcholine, glutamate, substance P, and CGRP from isolated slices of brain and spinal cord from several species following stimulation with either potassium or capsaicin (Dooley et al., 2000; Patel et al., 2000; Fehrenbacher et al., 2003; Brawek et al., 2008). However, the inhibitory effect of gabapentin and pregabalin may be stimulus-dependent, as illustrated in the neocortex, where the magnitude of inhibition of the release of noradrenaline was reduced when neurotransmitter release was evoked by electrical stimulation rather than potassium (Dooley et al., 2000). It has been suggested that α2δ ligands may only exert their inhibitory effects on neurotransmitter release in “sensitized” situations and may exert only limited effects in situations of normal physiology. For example, in the spinal cord, gabapentin was only able to exert its presynaptic inhibitory influence on postsynaptic currents in animals in which experimental diabetic neuropathy had been established with streptozotocin and not in unsensitized animals (Patel et al., 2000). Similarly, the pregabalin-mediated reductions in substance P and CGRP release in the spinal cord of the rat are manifest only in animals in which inflammation had been induced following pre-treatment with intraplantar Freund’s adjuvant and are absent in untreated animals (Fehrenbacher et al., 2003).

More recently, an additional mechanism of action has been suggested for gabapentin and pregabalin. In cell or neuronal cultures gabapentin and pregabalin were shown to inhibit the activation of the transcription factor NF-κB evoked by substance P (Park et al., 2008). If confirmed in additional studies, these observations might help explain the increased efficacy of gabapentin and pregabalin
PRE-CLINICAL MODELS OF NON-GI NEUROPATHIC PAIN

The anti-allodynic and anti-hyperalgesic properties of gabapentin and pregabalin have been established in a wide range of animal models and the literature is too extensive to review here. In summary, both of these α2δ ligands have been shown to manifest these properties in animal models of inflammatory, surgical, and neuropathic pain, including the inhibition of both the static and dynamic components of allodynia (for example; Field et al., 1997a,b, 1999). Interestingly, in a study of both sympathetically-maintained and sympathetically-independent neuropathic pain, pregabalin was particularly potent at inhibiting both tactile and cold allodynia when given by the intrathecal route, suggesting a predominantly spinal site of action, although the involvement of supraspinal centers cannot be ruled out (Han et al., 2007).

Pregabalin was unable to inhibit cold allodynia in the model of sympathetically-independent neuropathic pain when given via the intraperitoneal route (Han et al., 2007). Experiments involving direct recording from spinal neurons have demonstrated the ability of pregabalin to inhibit the C-fiber mediated response of spinal nociceptive-specific neurons, without any effect on the responsiveness of A-fibers (You et al., 2009). Further, pregabalin was also able to inhibit central sensitization of the spinal neurons induced by application of bee venom. Spinal transection confirmed that the effect of pregabalin in this study was likely to involve supraspinal centers, mediated through descending inhibitory controls (You et al., 2009).

PRE-CLINICAL MODELS OF GI SENSATION AND MOTILITY

Following the demonstration of the efficacy of gabapentin and pregabalin in animal models of neuropathic pain, investigations of the profile of these agents in small animal models of visceral pain followed. Initial focus was on understanding whether gabapentin and pregabalin might have utility in the treatment of IBS and so studies focused on models of rectal or colonic hypersensitivity. Caution needs to be applied when interpreting these data given the recent history of notable failure of these models to predict the recent history of notable failure of these models to predict the inflammatory stimulus in the proximal colon establishes a secondary hyperalgesia and allodynia in the distal colon, presumably through central sensitization at the level of the lumbar spinal cord, although possibly also involving higher centers. These central nervous system structures are the likely site of action of pregabalin in this model and in the absence of sensitization, pregabalin had no effect on sensation.

A series of studies with the prototype α2δ ligand gabapentin, confirmed that the effects on visceral pain were shared across the class and not restricted to pregabalin. In both mice and rats, gabapentin was shown to reduce the response evoked by intraperitoneal administration of acetic acid, a model of acute visceral pain. Gabapentin (50–200 mg/kg i.p.), dose-dependently inhibited the number of abdominal contractions evoked by intraperitoneal acetic acid when given 40 min ahead of the stimulus (Diop et al., 2002). The maximum effect was seen at 200 mg/kg and inhibited the abdominal response by approximately 75%. This dose of gabapentin impaired the performance of rats on the beam-balance test, suggestive of sedation, which can interfere with the interpretation of tests of analgesia, raising the possibility that the antinoceptive effect of gabapentin was secondary to sedative effects. In this study, the investigators also attempted to develop some mechanistic understanding of these observations and measured acute changes (over a 90-min observation) in the intrathecal levels of several amino acids. Intraperitoneal administration of acetic acid evoked large rises in both aspartate and glutamate. These increases were inhibited completely by prior administration of gabapentin (100 mg/kg i.p.). In addition, acetic acid also increased the intrathecal levels of the inhibitory amino acid serine, an increase that was also inhibited by gabapentin pre-treatment. Intrathecal levels of the inhibitory amino acid glycine was reduced to below baseline levels by gabapentin. In a broadly similar study, this time conducted in mice, Stepanovic-Petrovic et al. (2008) confirmed the activity of gabapentin to inhibit the nociceptive effects of peritoneal irritation evoked by acetic acid. In this study, intraperitoneal administration evoked a writhing response, characterized by abdominal contractions coupled with elongation of the body and extension of the hindlimbs. Intraperitoneal administration of gabapentin (10–70 mg/kg), 1 h before the acetic acid, dose-dependently inhibited the writhing response. Once again, this group compared the potency of gabapentin to inhibit in circumstances of prior inflammation or sensitization, which might be expected to lead to up-regulation of the NF-κB signaling pathway.
acetic-acid-induced writhing with its ability to impair motor function, assessed using the rotarod test (a test of performance in which the rodent is placed on a suspended horizontal rotating rod [not high enough to injure the animal but high enough that the animal avoids falling off] to measure balance, coordination and motor planning). In this study, gabapentin was devoid of activity in the rotarod test, even at doses of 2000 mg/kg, thus making it unlikely that the observed antinociceptive effects were occurring secondary to sedation. In an interesting study from Meymandi and Sepehri (2008), the antinociceptive effect of gabapentin (1–100 mg/kg i.p.) was confirmed in the acetic acid-induced writhing model. In the same study, the dose-response curve to morphine was also constructed and then a low effective dose of gabapentin was given as a combination with a sub-therapeutic dose (0.25 mg/kg i.p.) of morphine. This combination produced a synergistic effect, as writhing was inhibited by over 90% compared to control levels. Similarly, when the sub-therapeutic dose of morphine was combined with a sub-therapeutic dose of gabapentin (10 mg/kg i.p.), a synergistic response was observed, with writhing inhibited by approximately 70%. Interestingly, these synergistic effects were not inhibited by treatment with naloxone. Similar observations, of a synergistic interaction between gabapentin and morphine in models of visceral pain have been made previously in a rat model of experimental pancreatitis induced by bradykinin infusion into the pancreas (Smiley et al., 2004). In this model, gabapentin (100–300 μg intrathecally) only modestly inhibited the behavioral response to bradykinin. However, when the 300 μg intrathecal dose of gabapentin was combined with low intrathecal doses of morphine, shown previously to have modest if any inhibitory effects in this model, significant inhibition of all aspects of the behavioral response to bradykinin was observed. These observations taken together illustrate the inhibitory effect of gabapentin on visceral pain, strongly support the concept that this effect is not underwritten or confounded by inhibiting arousal and point to potential synergy with other antinociceptive mechanisms. These data also provide in vivo evidence to support the hypothesis that gabapentin reduces the release of excitatory and inhibitory neurotransmitters in the spinal cord.

Recently, a study has been published comparing the effect of pregabalin in the TNBS model of acute hypersensitivity with a model of acute hypersensitivity induced by restraint stress (Ohashi-Doi et al., 2010). As one might predict from previous data, pregabalin (10–100 μg/kg p.o.) reduced colonic nociceptive thresholds dose-dependently in animals sensitized previously with TNBS. In the stress restraint model, increased fecal output in terms of number of pellets and fecal weight was observed during the period of restraint stress. Pregabalin, over the same dose range as examined in the TNBS model, also dose-dependently inhibited the stress-induced increases in fecal output, but had no effect on naive, unstressed rats. This is the only demonstration to date that pregabalin can modulate stress-induced defecation in rats. A comparison of the effects in the two models suggests that pregabalin may be more potent at inhibiting the stress-induced increases in defecation than at inhibiting TNBS-induced colonic hypersensitivity.

The majority of studies of the effects of α₂δ ligands on visceral pain have been restricted to acute models and largely to those evoked by chemical irritants or pro-inflammatory stimuli. More recently investigators have studied the effects of gabapentin and pregabalin in models where less invasive and possibly more physiologically relevant stimuli have been used to evoke an acute or chronic phenotype. In a rat model, where repeated tonic colorectal distension induces hypersensitivity, oral pregabalin (10 and 30 mg/kg) inhibited the development of hyperalgesia (Million et al., 2007). Moreover, using Fos staining to indicate neuronal activation, a single oral dose of pregabalin (30 mg/kg) blunted the activation of lumbarocaudal spinal neurones. These data raise the possibility that in this model, pregabalin inhibits spinal sensitization and so inhibits the development of hyperalgesia. It has been demonstrated that maternal separation of rats in the early neonatal period, a presumably highly stressful stimulus, can give rise to hyperalgesia, revealed by colorectal distension, that is sustained for many weeks after the original stress (Coutinho et al., 2002). In an elegant study, to date only published as an abstract, Coelho et al. (2008) confirmed that a dose of gabapentin (30 mg/kg s.c.) that inhibited acute visceral pain evoked by intraperitoneal acetic acid, was also able to inhibit the pain behaviors evoked by colorectal distension in rats that had undergone maternal separation 9–11 weeks earlier.

New α₂δ ligands are starting to appear in literature, but to date, only one of these, PD-217014, which has similar binding affinity at the α₂δ binding site as pregabalin, has been investigated in an animal model of visceral hypersensitivity (Ohashi et al., 2008). In the TNBS model described previously, oral dosing of PD-217014 (3–100 mg/kg) dose-dependently inhibited the reduction in colonic nociception threshold observed 7 days after TNBS administration. Maximum inhibition was reached at 60 mg/kg and the inhibition at this dose was long lasting, reaching a peak at 2 h post-dose and lasting for between 6 and 8 h. Pharmacokinetic/pharmacodynamic (PK/PD) analysis clearly demonstrated that maximum anti-hyperalgesic effect coincided with peak plasma exposures. Interestingly, whilst the anti-hyperalgesic effect persisted at 6 h post-dose, plasma levels had at this time diminished to low levels. These observations suggest that the persistence of the pharmacological effect of PD-217014 is not simply related to plasma exposure and this phenomenon requires further investigation.

In a recent study, Ravnefjord et al. (2008) demonstrated in normal, unsensitized rats that pregabalin (10–200 μmol/kg p.o.) inhibited the visceralosomatic response to phasic, noxious colorectal distension at 80 mmHg as well as the visceralosomatic response to ascending (10–80 mmHg), phasic distension. In this study, the highest dose of 200 μmol/kg p.o. also inhibited the increases in cardiovascular parameters (blood pressure and heart rate) seen in response to noxious distension at 80 mmHg. However, one of the most interesting observations in this study, and one that reveals another potential mechanism of action of pregabalin to reduce pain thresholds in these distension models, was an apparent leftward shift in the colonic pressure-volume relationship. These observations suggest that pregabalin may increase the compliance of the colon in response to distension and by this mechanism could effectively reduce the intensity of the noxious stimulus. Similarly, this could be a mechanistic explanation for the observations of antinociceptive activity in models employing colorectal distension as a nociceptive stimulus.
CLINICAL EVIDENCE AND POTENTIAL UTILITY IN IBS

To date only two clinical studies have been published (Lee et al., 2005; Houghton et al., 2007) assessing the effect of these compounds on visceral sensitivity in IBS and one abstract in healthy volunteers (Chua et al., 2009). No results from clinical trials examining the efficacy of α2δ ligands on symptoms in IBS patients have yet appeared in literature. However, there is one investigator-sponsored small placebo-controlled trial of pregabalin in IBS (NCT00977197), another investigator sponsored study looking at the effect of pregabalin on colonic sensorimotor function in healthy volunteers (NCT01094808) and a company-sponsored clinical trial assessing the effect of the new generation δ2 ligand, PD-217014 in IBS (NCT00139672) currently listed on the US National Institute of Health ClinicalTrial.gov website.

The first study published assessed the effect of gabapentin (300 mg/day for the first 3 days and the 600 mg/day for the subsequent 2 days) on rectal sensitivity to balloon distension in IBS patients with diarrhea diagnosed using Rome II (IBS-D; Lee et al., 2005). The authors reported that the threshold pressures for bloating, discomfort and pain, and rectal compliance all significantly increased after gabapentin but not following placebo. The increase in rectal tone seen after meal ingestion was unaffected. Unfortunately however, no direct comparison was made with placebo in this study, so the significance of their gabapentin findings needs to be viewed with caution. The second study published by the authors assessed the effect of pregabalin (titrated from 50 mg tid to 200 mg tid over 3 weeks) in IBS patients who exhibited rectal hypersensitivity to mechanical distension (Houghton et al., 2007). In comparison to placebo, pregabalin was shown to significantly increase or normalize the sensory thresholds for pain (anti-allodynic effect), along with first sensation and desire to defecate (anti-hyperalgesic effect), without desensitizing (i.e., make hypersensitive) the perception of distension. If confirmed by larger studies and the results from the study currently in progress assessing the effect of pregabalin on colonic sensorimotor function in healthy volunteers (NCT01094808) proves to be negative, then this would suggest that as shown in the animal models, desensitization only occurs in the presence of an hypersensitive state. Such a compound would be most desirable for treatment of IBS and confirms studies in healthy volunteers showing that gabapentin reduces signs of central sensitization induced by intradermal capsaicin (i.e., the area of brush and pinprick hyperalgesia) but not spontaneous or evoked pain induced by capsaicin (Gottrup et al., 2004). Similarly, a more recent study only published in abstract form to date, showed that pregabalin prevents the development of secondary hyperalgesia in the proximal esophagus after distal esophageal acidification but had no effect on the primary hyperalgesia induced in the distal esophagus (Chua et al., 2009), supporting a central mode of action for pregabalin in reduction of pain.

In addition to pregabalin's effect on visceral sensation, and as with the gabapentin rectal motor–sensory study (Lee et al., 2005) and in the animal models (Ravnefjord et al., 2008) described previously, rectal compliance increased following pregabalin, although there appeared to be no association with the observed reduction in visceral pain (Houghton et al., 2007). This suggests additional mechanisms of action, as yet to be explored. Similar observations have been seen before with both clonidine and nitroglycerine both increasing gastric compliance but only clonidine reducing pain perception (Thumshirn et al., 1999).

Generalized anxiety disorder, as with IBS, is a common disorder. Furthermore studies have shown that 32–58% of patients with IBS meet the diagnostic criteria for GAD (Lydard, 2001), a condition which has recently been shown to improve following treatment with pregabalin (Stein et al., 2009). As well as improving overall anxiety levels in GAD patients, the study showed that treatment with pregabalin also led to an improvement in GI symptoms that very often coexist in these patients and similar to those seen in functional GI disorders, such as IBS (Stein et al., 2009). This raises the possibility that GI symptoms might improve as a consequence of the treatment of anxiety by pregabalin. Neither the presence of GAD nor levels of co-existing anxiety or depression were measured in the study of rectal hypersensitivity (Houghton et al., 2007), but the observation that pregabalin increased the sensory thresholds for first sensation and the desire to defecate, sensations not normally expected to be under significant psychological influence, might suggest that the anxiolytic properties of pregabalin were not playing a major role in modulating visceral sensation. In support of this hypothesis, other studies using anxiolytic agents, such as buspirone or antidepressants such as amitriptyline have shown no effect on colonic sensitivity to balloon distension (Mertz et al., 1998; Chial et al., 2003; Morgan et al., 2005). However, these observations do not exclude the possibility an anxiolytic effect for pregabalin in amelioration of IBS symptoms, especially in patients with anxiety-induced increased defecation (as implicated by the acute restraint stress animal model; Ohashi-Doi et al., 2010), but clinical trials are required in which psychological symptoms along with the cardinal IBS symptoms are measured to address the true efficacy of these agents in the treatment of IBS.

Other factors that might influence rectal sensation are the adverse effects associated with pregabalin, namely dizziness and/or somnolence. However, in the study of Houghton et al. (2007) these side effects had resolved in the majority of patients by the time sensitivity was assessed, and the change in sensory threshold in these patients was no different from that seen in those still retaining mild/moderate side effects, supporting data from animal studies (Ohashi-Doi et al., 2010).

Furthermore the improvement in sensory threshold tended to associate with a reduction in abdominal pain (Houghton et al., 2007), supporting the observations that pregabalin improves GI symptoms associated with GAD (Stein et al., 2009), and pain in patients with fibromyalgia (Hauser et al., 2009; Smith and Barkin, 2010; Straube et al., 2010). The results from the ongoing clinical trials are eagerly awaited, and whether the patients have been appropriately phenotyped to identify any sub-group improvement based on their hypersensitivity or anxiety status also remains to be revealed.

CONCLUSION

Gabapentin and pregabalin are valuable medicines being used for the treatment of a number of conditions, including neuropathic pain, epilepsy, anxiety, and fibromyalgia. A body of evidence implicates binding to the α2δ subunits of voltage-gated calcium channels on presynaptic neuronal membranes as their most likely
mechanism of action. However, recent data also points at potential additional mechanisms within the cell which may underwrite some of their chronic effects and also indicates potential modulation of pro-inflammatory pathways through inhibition of NF-kB signaling. The modulation of calcium fluxes evoked by gabapentin and pregabalin has been shown to reduce the release of a broad range of both excitatory and inhibitory neurotransmitters, primarily in the central nervous system and hence this mechanism has great potential to influence signaling pathways, including those involved in pain transmission. Emerging data supports a role for the α2δ subunit in neurotransmission in the enteric nervous system, but the functional importance of these observations has yet to be fully elucidated.

Data from animal models provides evidence for the inhibition of both visceral nociception and GI function by gabapentin and pregabalin in animals in which hypersensitivity has been induced by either an inflammatory stimulus or stress, but largely illustrates an absence of such activity on basal sensitivity or function.

When particularly strong noxious stimuli are used (acetic acid or distension to high pressures) effects on sensation in unsensitized animals can be observed. These observations are in concordance or distension effects on sensation in unsensitized animals. In patients with IBS, both gabapentin and pregabalin have been shown to reduce rectal sensitivity to balloon distension and in the study with pregabalin, anti-allodynia, and anti-hyperalgesia was demonstrated in subjects with pre-characterized rectal hypersensitivity. Data is expected soon from a similar study in healthy volunteers which will illustrate whether these agents have, like in many animal models, little effect on sensory thresholds in subjects without hypersensitivity. Both animal and clinical data also suggest that α2δ ligands may alter intestinal compliance and the significance of this needs further investigation. These data, supported by observations from animal studies, support further investigation of α2δ ligands in disorders characterized by visceral hypersensitivity such as IBS. Carefully controlled, randomized clinical trials will be needed to fully understand the potential of these agents to treat these bothersome conditions.

REFERENCES
Agrawal, A., Houghton, L. A., Lea, R., Reilly, B., and Whorwell, P. J. (2008). Abdominal bloating and distension in irritable bowel syndrome: a role for visceral sensation. Gastroenterology 134, 1882–1889.

Almansa, C., Rey, E., Sanchez, G., Sanchez, A. A., and Diaz-Rubio, M. (2009). Prevalence of functional gastrointestinal disorders in patients with fibromyalgia and the role of psychologic distress. Clin. Gastroenterol. Hepatol. 7, 438–445.

Anand, P., Aziz, Q., Willert, R., and Van Oudenhove, L. (2007). Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol. Motil. 19, 29–46.

Ben-Menachem, E. (2004). Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45(Suppl. 6), 13–18.

Bouin, M., Plourde, V., Boivin, M., Riberyd, M., Lupien, F., Laganiere, M., Verrier, P., and Poitras, P. (2002). Rectal distension testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 122, 1771–1777.

Brawek, B., Löfler, M., Dooley, D. J., Weyerbrock, A., and Feuerstein, T. J. (2008). Differential modulation of K+evoked 3H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch. Pharmacol. 376, 301–307.

Catterall, W. A., Perez-Reyes, E., Snutch, T. P., and Striessnig, J. (2005). International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57, 411–425.

Chial, H. J., Camilleri, M., Ferber, L., Delgado-Aros, S., Burton, D., McKinzie, S., and Zinsmeister, A. R. (2003). Effects of venlafaxine, buspirone and placebo on colonic sensorimotor function in healthy humans. Clin. Gastroenterol. Hepatol. 1, 211–218.

Chikara, D. K., van Tilburg, M. A., Bliss-Martin, N., and Whitehead, W. E. (2008). Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am. J. Gastroenterol. 103, 765–774.

Chua, Y. C., Ng, K. S., Jafari, J., Sharma, A., Surguy, S., Yazaki, E., Jula, P. O., Knowles, C. H., and Aziz, Q. (2009). Pregabalin prevents development of esophageal hypersensitivity to esophageal acid infusion in healthy volunteers. Gastroenterology 138(Suppl. 1), 933; Abstract.

Coelho, A. M., O’Mahony, S., Taylor, C., Wheeldon, A., Fitzgerald, P., Dinan, T. G., Cryan, J. F., Lee, K., and Winchester, W. J. (2008). Gabapentin reverses colo-rectal distension-induced visceral pain behaviours in rat models of acute and chronic visceral hypersensitivity. Gastroenterology 134, A573.

Coffin, B., Bouhassira, D., Sabate, J.-M., Barbe, L., and Jian, R. (2004). Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 53, 1465–1470.

Cole, R. L., Lechner, S. M., Williams, M. E., Prodanovich, P., Bleicher, L., Varney, M. A., and Gu, G. (2005). Differential distribution of voltage-gated calcium channel alpha2-delta (α2δ) subunit mRNA-containing cells in the rat central nervous system and the dorsal root ganglia. J. Comp. Neurol. 491, 246–269.

 Coutinho, S. V., Plotsky, P. M., Sablak, M., Miller, J. C., Zhou, H., Bayati, A. I., McRoberts, J. A., and Mayer, E. A. (2002). Neonatal maternal separation alters stress-induced responses to visceroasomatic nociceptive stimuli in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G307–G316.

Diop, L., Raymond, E., Fargeau, H., Petoux, F., Chovet, M., and Doherty, A. M. (2002). Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allo-dynia in the rat. J. Pharmacol. Exp. Ther. 302, 1013–1022.

Dooley, D. J., Donovan, C. M., and Pugsley, T. A. (2000). Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther. 295, 1086–1093.

Eutamene, H., Coelho, A.-M., Theodorou, V., Tououlouse, M., Chovet, M., Doherty, A., Fioramonti, J., and Bueno, L. (2000). Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J. Pharmacol. Exp. Ther. 295, 162–167.

Fehrenbacher, J. C., Taylor, C. P., and Vasko, M. R. (2003). Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105, 133–141.

Feng, Y., Gui, M., and Willis, W. D. (2003). Gabapentin markedly reduces acetic acid-induced visceral nociception. Anesthesiology 98, 729–733.

Field, M. J., Cox, P. J., Stott, E., Melrose, H., Offord, J., Su, T. Z., Bramwell, S., Corradoini, L., England, S., Winks, J., Kinloch, R. A., Hendrich, J., Dolphin, A. C., Webb, T., and Williams, D. (2006). Identification of the alpha2-delta1 subunit of voltage-dependent calcium channels as a molecular target for pain medi-ating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. U.S.A. 103, 17537–17542.

Field, M. J., Oles, R. L., Lewis, A. S., McLeary, S., Hughes, J., and Singh, L. (1997a). Gabapentin (neurontin) and S(+)-3-isobutylglycine represent a novel class of selective antihyperalgesic agents. Br. J. Pharmacol. 121, 1513–1522.
Field, M. J., Holloman, E. F., McCleary, S., Hughes, J., and Singh, L. (1997b). Evaluation of gabapentin and S-(+)-3-isobutylglyxa in a rat model of postoperative pain. J. Pharmacol. Exp. Ther. 282, 1242–1246.

Field, M. S., McCleary, S., Hughes, J., and Singh, L. (1999). Gabapentin, and Pregabalin but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80, 391–398.

Francis, C. Y., Houghton, L. A., Whorwell, P. J., Morris, J., and Bradbury, J. (1995). Enhanced sensitivity of the whole gut in patients with irritable bowel syndrome. Gastroenterology 108, 601.

Gong, Q., Zhang, H., Kohler, W., Li, S., and Tu, Z. T. (2001). Tissue-specific expression and gabapentin-binding properties of calcium channel alpha2delta subunit subtypes. J. Membr. Biol. 184, 35–43.

Gottrup, H., Juhl, G., Kristensen, A. D., Lai, R., Chizh, B. A., Brown, J., Fischer, B. W., and Jensen, T. S. (2004). Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 101, 1400–1408.

Hammonds, R. M., Houghton, L. A., Whorwell, P. I., Morris, J., Francis, C. Y., and Mills, J. (1998). Whole gut sensitivity in constipation predominant irritable bowel syndrome: 80% of patients exhibit an abnormality. Gastroenterology 114(2 Pt 2), G1337.

Han, D. W., Kweon, T. D., Lee, J. S., and Lee, Y. W. (2007). Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain. Yonsei Med. J. 48, 41–47.

Hauser, W., Bernardy, K., Uceyler, N., and Sommer, C. (2009). Treatment of fibromyalgia syndrome with gabapentin and pregabalin—a meta-analysis of randomized controlled trials. Pain 145, 69–81.

Hendrich, J., Van Minh, A. T., Heblich, F., Nieto-Rostro, M., Watschinger, K., Strissinger, J., Watten, J. Davies, A., and Dolphin, A. C. (2008). Pharmacological disruption of calcium channel trafficking by the αδ ligand gabapentin. Proc. Natl. Acad. Sci. U.S.A. 105, 3628–3633.

Heymen, S., Maixner, W., Whitehead, W. E., Klatzkin, R. K., Mechlin, B., and Light, K. C. (2010). Central processing of noxious somatic stimuli in patients with irritable bowel syndrome compared with healthy controls. Clin. J. Pain 26, 104–109.

Houghton, L. A., Fell, C., Whorwell, P. J., Jones, L., Sudworth, D. P., and Gale, J. D. (2007). Effect of second-generation αδ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56, 1218–1225.

Huckle, R. (2004). Pregabalin Pfizer. Care. Opin. Investig. Drugs 5, 82–89.

Klugbauer, N., Lacinová, L., Marais, E., Hobom, M., and Hofmann, F. (1999). Molecular diversity of the calcium channel alpha2delta subunit. J. Neurosci. 19, 684–691.

Knowles, C. H., and Aziz, Q. (2009). Basic and clinical aspects of gastrointestinal pain. Pain 141, 191–209.

Labus, J., Vianna, E. P. M., Tillisch, K., Naliboff, B., and Mayer, E. A. (2009). Bladder response during pelvic visceral distension in healthy controls and patients with irritable bowel syndrome. Neurogastroenterol. Motil. 21(Suppl. 1), 80; Abstract 267.

Lee, K. J., Kim, J. H., and Cho, S. W. (2005). Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 22, 981–988.

Levy, R. L., Olden, K. W., Naliboff, B. D., Bradley, L. A., Francisconzi, C., Drossman, D. A., and Creed, F. (2006). Psychosocial aspects of functional gastrointestinal disorders. Gastroenterology 130, 1447–1458.

Longstreth, F., Thompson, A. W., Chey, W. D., Houghton, L. A., Meinr, F., and Spiller, R. (2006). Functional bowel disorders. Rome III. Gastroenterology 130, 1480–1491.

Lydiard, R. B. (2001). Irritable bowel syndrome, anxiety, and depression: what are the links? J. Clin. Psychiatry 62(Suppl. 8), 38–45; Discussion 24.

Mayer, E. A., and Gebhart, G. F. (1994). Mechanosensitivity and increases colonic nociceptor density in healthy controls and patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 22, 981–988.

Nguyen, T. V., Turner, K., Nash, M., and Furness, J. B. (2010). Identification of subunits of voltage-gated calcium channels and actions of pregabalin on primary afferent neurones in the guinea-pig ileum. Neurogastroenterol. Motil. 22, e301–e308.

Ohashi, K., Kawai, J., Ninimiyai, N., Taylor, C., and Kurebayashi, Y. (2008). Effect of a new αδ ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzen sulfonic acid in rats. Pharmacology 81, 144–150.

Ohashi-Doi, K., Gale, J. D., and Kurebayashi, Y. (2010). Pregabalin inhibits accelerated defecation and decreased colonic nociceptive threshold in sensitized rats. Eur. J. Pharmacol. 645, 107–112.

Park, S., Ahn, E. S., Han, D. W., Lee, J. H., Min, K. T., Kim, H., and Hong, Y. W. (2008). Pregabalin and gabapentin inhibit substance P-induced NF-kappaB activation in neuroblastoma cells. J. Cell. Biochem. 105, 414–423.

Patel, M. K., Gonzalez, M. I., Bramwell, S., Pinnock, R. D., and Lee, K. (2000). Gabapentin inhibits excitatory synaptic transmission in the hyperalgesic spinal cord. Br. J. Pharmacol. 130, 1731–1734.

Pelce, M., Arsenault, M., Poitras, P., Rainville, P., and Bouin, M. (2010). Widespread hypersensitivities is related to altered pain inhibition processes in irritable bowel syndrome. Pain 148, 49–58.

Posserud, I., Syros, A., Lindstrom, L., Tack, J., Abrahamsson, H., and Simren, M. (2007). Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 133, 1113–1123.

Qin, N., Yagel, S., Momplaisir, M. L., Codd, E. E., and D’Andrea, M. R. (2002). Molecular cloning and characterization of the human voltage-gated calcium channel αδ subunit. Mol. Pharmacol. 62, 485–496.

Ravneford, J., Brusberg, M., Larson, H., Lindström, E., and Martínez, V. (2008). Effects of pregabalin on visceral pain responses and colonic compliance in rats. Br. J. Pharmacol. 155, 407–416.

Saito, Y. A., and Talley, N. J. (2008). Genetics of irritable bowel syndrome. Am. J. Gastroenterol. 103, 2100–2104.

Sarkar, S., Aziz, Q., Woolf, C. J., Hobson, A. R., and Thompson, D. G. (2000). Contribution of central sensitization to the development of non-cardiac chest pain. Lancet 356, 1154–1159.

Schlicker, E., Reimann, W., and Göthert, M. (2005). Gabapentin decreases monosodium release without affecting acetylcholine release in the brain. Arzneimittelforschung 35, 1347–1349.

Seminowicz, D. A., Labus, J. S., Bueller, J. A., Tillisch, K., Naliboff, B. D., Bushnell, M. C., and Mayer, E. A. (2010). Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 139, 48–57.

Smiley, M. M., Lu, Y., Vera-Portocarrero, L. P., Zidan, A., and Westlund, K. N. (2004). Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. Anesthesiology 101, 759–765.

Smith, H. S., and Barkin, R. (2010). Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am. J. Ther. 17, 418–439.

Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, I. A., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., and Whorwell, P. J. (2007). Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56, 1770–1798.

Spiller, R., and Garsed, K. (2009). Postinfectious irritable bowel syndrome. Gastroenterology 136, 1979–1988.

Stefan, P., Spadoni, E., and Bernardi, G. (1998). Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 37, 83–91.

Stein, D. J., Bruce, L. R., Herman, B. K., and Mandel, F. S. (2009). Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int. Clin. Psychopharmacol. 24, 126–132.
Stepanovic-Petrovic, R. M., Tomic, M. A., Vuckovic, S. M., Paranos, S., Ugresic, N. D., Prostran, M. S., Milovanovic, S., and Boskovic, B. (2008). The antinociceptive effects of anticonvulsants in a mouse visceral pain model. Anesth. Analg. 106, 1897–1903.

Straube, S., Derry, S., Moore, R. A., Paine, J., and McQuay, H. J. (2010). Pregabalin in fibromyalgia—responder analysis from individual patient data. BMC Musculoskelet. Disord. 11, 150. doi: 10.1186/1471-2474-11-150.

Sutton, K. G., Martin, D. J., Pinnock, R. D., Lee, K., and Scott, R. H. (2002). Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br. J. Pharmacol. 135, 257–265.

Taylor, C. P. (2009). Mechanisms of analgesia by gabapentin and pregabalin – calcium channel \( \alpha_2-\delta \) (Cav \( \alpha_2-\delta \)) ligands. Pain 142; 13–16.

Taylor, C. P., and Garrido, R. (2008). Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (\( \alpha_1 \)) type 1 protein. Neuroscience 155, 510–521.

Thurnshirn, M., Camilleri, M., Choi, M. G., and Zinsmeister, A. R. (1999). Modulation of gastric sensory and motor functions by nitrergic and \( \alpha_2-\delta \)-adrenergic agents in humans. Gastroenterology 116, 573–583.

Tzéllos, T. G., Papazisis, G., Toulis, K. A., Sardeli, C. H., and Kouvelas, D. (2010). \( \alpha_2-\delta \) ligands gabapentin and pregabalin: future implications in daily clinical practice. Hippokratia 14, 71–75.

van Hooft, J. A., Dougherty, J. I., Endeman, D., Nichols, R. A., and Wadman, W. J. (2002). Gabapentin inhibits presynaptic \( \text{Ca}^{2+} \) influx and synaptic transmission in rat hippocampus and neocortex. Eur. J. Pharmacol. 449, 221–228.

Van Oudenhove, L., and Aziz, Q. (2009). Recent insights on central processing and psychological processes in functional gastrointestinal disorders. Dig. Liver Dis. 41, 781–787.

Verne, G. N., Robinson, M. E., and Price, D. D. (2001). Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 93, 7–14.

Whitehead, W. E., Palsson, O., and Jones, K. R. (2002). Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 122, 1140–1156.

Whitehead, W. E., and Palsson, O. S. (1998). Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 115, 1263–1271.

Whorwell, P. J., McCallum, M., Creed, F. H., and Roberts, C. T. (1986). Non-colonic features of irritable bowel syndrome. Gut 27, 37–40.

You, H. J., Lei, J., and Arendt-Nielsen, L. (2009). Selective inhibitory effects of pregabalin on peripheral C but not A-delta fibers mediated nociception in intact and spinalized rats. Neuroscience 164, 1845–1853.

Conflict of Interest Statement: Dr. Jeremy Gale is an employee and shareholder of Pfizer. Professor Lesley A. Houghton has served as a speaker, a consultant, and/or an advisory board member for Novartis, Pfizer, Solvay Pharmaceuticals, GlaxoSmithKline, and Danone Research; and the Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, USA has received research funding from Edusa Pharmaceuticals, Inc., USA.

Received: 08 February 2011; accepted: 29 May 2011; published online: 09 June 2011.

Citation: Gale JD and Houghton LA (2011) \( \alpha_2-\delta \) ligands and irritable bowel syndrome. Front. Pharmacol. 2:28. doi: 10.3389/fphar.2011.00028

This article was submitted to Frontiers in Gastrointestinal Pharmacology, a specialty of Frontiers in Pharmacology. Copyright © 2011 Gale and Houghton. This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.